Sees FY25 revenue $16.8B-$17.2B, consensus $17.24B
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEVA:
- Teva, Alvotech: FDA approves interchangeability for SELARSDI with Stelara
- Teva, Alvotech announce FDA approval of interchangeability for SELARSDI
- Teva Pharmaceutical Industries Limited (TEVA) Q1 Earnings Cheat Sheet
- Teva price target lowered to $20 from $24 at HSBC
- Teva Pharmaceutical’s Strategic Focus on EBITDA Growth and Cost Efficiencies Drives Buy Rating